Filing Flows › Bionano Genomics (BNGO) › Q2 2026 › vs Q1 2026
Bionano Genomics (BNGO) Q2 2026 vs Q1 2026 (quarter over quarter)
Bionano Genomics's revenue rose $1.5M (+22%) from $6.7M in Q1 2026 to $8.2M in Q2 2026. The biggest changes: Product +$1.6M (+26%); Product and Service Other −$115K (-19%).
Bionano Genomics, Q2 2026: revenue $8.2M (+21% year over year), operating margin -88.3%, net loss $7.4M, operating cash flow −$4.7M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumable Revenue | $4.3M | $3.9M | $385K | +10% |
| Instrument Revenue | $2.0M | $962K | $1.1M | +112% |
| Software Revenue | $1.4M | $1.2M | $139K | +11% |
| Product | $7.7M | $6.1M | $1.6M | +26% |
| Product and Service Other | $478K | $593K | −$115K | -19% |
| Revenue | $8.2M | $6.7M | $1.5M | +22% |
| Net loss | $7.4M | $8.3M | −$880K | -11% |
| Costs & expenses | $15.6M | $15.0M | $604K | +4% |
| Operating costs | $15.4M | $14.6M | $805K | +6% |
| Interest & other, net | $198K | $396K | −$198K | -50% |
| Income tax | $7K | $10K | −$3K | -30% |
| Cost of revenue | $3.9M | $3.4M | $422K | +12% |
| Research & development | $3.0M | $3.1M | −$151K | -5% |
| SG&A | $8.5M | $8.0M | $534K | +7% |
| Operating cash sources | $7.9M | $8.7M | −$760K | -9% |
| Depreciation & amortization | $2.3M | $2.3M | −$14K | -0.6% |
| Share-based compensation | $970K | $670K | $300K | +45% |
| Cash used in operations | $4.7M | $5.7M | −$1.0M | -18% |
| Net loss absorbed | $7.4M | $8.3M | −$880K | -11% |
| Working capital & other | $513K | $393K | $120K | +31% |
Questions
How much did Bionano Genomics's revenue grow quarter over quarter in Q2 2026?
Bionano Genomics's revenue rose $1.5M (+22%) from $6.7M in Q1 2026 to $8.2M in Q2 2026.
What drove Bionano Genomics's revenue change in Q2 2026?
Product +$1.6M (+26%); Product and Service Other −$115K (-19%).